Business UpdateJul 2, 2026, 08:02 AM
Jyong Biotech Advances Botreso® Global Licensing at BIO 2026
AI Summary
Jyong Biotech announced its participation in the BIO International Convention 2026, where it engaged in discussions with global pharmaceutical companies and investors. The company presented its botanical new drug candidate, Botreso® (API-1), which targets benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) and has completed four Phase III clinical trials. Jyong Biotech is accelerating NDA preparations and global licensing plans to commercialize Botreso® in key markets like the US, Europe, and Asia, capitalizing on the projected 35-40% growth in the BPH/LUTS market by 2035.
Key Highlights
- Jyong Biotech participated in the BIO International Convention 2026.
- Company held in-depth discussions with global pharmaceutical companies and investors.
- Presented botanical new drug candidate, Botreso® (API-1), for BPH and LUTS.
- Completed four Phase III clinical trials for Botreso® in the US and Taiwan.
- Accelerating New Drug Application (NDA) preparations and global licensing plans.
- Aims to expedite commercialization in US, Europe, and Asia through partnerships.
- BPH/LUTS market projected to grow 35-40% between 2021 and 2035.
Price Impact
More from MENS